Protein restriction and AST-120 improve lipoprotein lipase and VLDL receptor in focal glomerulosclerosis

Kidney International

Volumn 64, Issue 5, 2003, Pages 1780-1786

  Sato, Tadashi ^b   Liang, Kaihui ^b   Vaziri, Nosratola D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

AST 120; Glomerulosclerosis; Hypercholesterolemic Imai rat; Hyperlipidemia; Lipoprotein lipase; Low protein diet; Renal failure; VLDL receptor

Indexed keywords

ADSORBENT; AST 120; LIPOPROTEIN LIPASE; RECEPTOR PROTEIN; TRIACYLGLYCEROL LIPASE; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; ENZYME ACTIVITY; FOCAL GLOMERULOSCLEROSIS; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOALBUMINEMIA; HYPOTHESIS; IMMUNODETECTION; KIDNEY DISEASE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN RESTRICTION; PROTEINURIA; RAT; RAT STRAIN; SKELETAL MUSCLE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 0142156124     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00281.x     Document Type: Article

References (39)

1. YOSHIKAWA Y, YAMASAKI K: Renal lesions of hyperlipidemic Imai rats: A spontaneous animal model of focal glomerulosclerosis. Nephron 59:471-476, 1991
2. SAKEMI T, BABA N, YOSHIKAWA Y: Angiotensin-converting enzyme inhibition attenuates hypercholesterolemia and glomerular injury in hyperlipidemic Imai rats. Nephron 62:315-321, 1992
3. SATO T, LIANG K, VAZIRI ND: Downregulation of lipoprotein lipase and VLDL receptor in rats with focal glomerulosclerosis. Kidney Int 61:157-162, 2002
4. VAZIRI ND, SATO T, LIANG K: Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis. Kidney Int 63:1756-1763, 2003
5. VAZIRI ND, LIANG K, PARK JS: Acquired lecithin: Cholesterol acyltransferase (LCAT) deficiency in nephrotic syndrome. Am J Physiol Renal Physiol 49:F823-F829, 2001
6. LIANG K, VAZIRI ND: Gene expression of lipoprotein lipase in experimental nephrosis. J Lab Clin Med 130:387-394, 1997
7. LIANG K, VAZIRI ND: Acquired VLDL receptor deficiency in experimental nephrosis. Kidney Int 51:1761-1765, 1997
8. LIANG KH, OVEISI F, VAZIRI ND: Gene expression of hepatic cholesterol 7 alpha-hydroxylase in the course of puromycin-induced nephrosis. Kidney Int 49:855-860, 1996
9. VAZIRI ND, LIANG K: Downregulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int 50:887-893, 1996
10. VAZIRI ND, LIANG KH: Upregulation of Acyl-Coenzyme A: Cholesterol acyltransferase (ACAT) in nephrotic syndrome. Kidney Int 61:1769-1775, 2002
11. VAZIRI ND, LIANG KH: Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis. Kidney Int 48:1979-1985, 1995
12. VAZIRI ND, LIANG K: Downregulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int 50: 1928-1935, 1996
13. VAZIRI ND, WANG XQ, LIANG K: Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. Am J Physiol Renal Physiol 273:F925-F930, 1997
14. VAZIRI ND, LIANG K: Downregulation of VLDL receptor expression in chronic experimental renal failure. Kidney Int 51:913-919, 1997
15. LIANG K, VAZIRI ND: Upregulation of acyl-CoA: Cholesterol acyltransferase in chronic renal failure. Am J Physiol Endo Metab 283:E676-E681, 2002
16. VAZIRI ND, LIANG K, PARKS JS: Downregulation of hepatic lecithin: Cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int 59:2192-2196, 2001
17. ASCENCIO C, TORRES N, SANDOVAL RL, et al: Reduced kidney branched chain aminotransferase expression in puromycin amino-nucleoside-induced nephrotic syndrome. Life Sci 61:2407-2415, 1997
18. GIORDANO M, DE FEO P, LUCIDI P, et al: Effects of dietary protein restriction on fibrinogen and albumin metabolism in nephrotic patients. Kidney Int 60:235-242, 2001
19. RODRIGO R, BRAVO I, PINO M: Proteinuria and albumin homeostasis in the nephrotic syndrome. Effect of dietary protein intake. Nutr Rev 54:337-347, 1996
20. MIYAZAKI T, AOYAMA I, ISE M, et al: An oral sorbent reduces overload of indoxyl sulfate and gene expression of TGF-beta1 in uremic rat kidneys. Nephrol Dial Transplant 15:1773-1781, 2000
21. AOYAMA I, MIYAZAKI T, TAKAYAMA F, et al: Oral adsorbent ameliorates renal TGF-beta1 expression in hypercholesterolemic rats. Kidney Int 56(Suppl 71):S193-S197, 1999
22. SANAKA T, SUGINO N, TERAOKA S, OTA K: Therapeutic effects of oral sorbent in undialyzed uremia. Am J Kidney Dis 2:97-103, 1988
23. NIWA T, NOMURA T, SUGIYAMA S, et al: The protein metabolite hypothesis, a model for the progression of renal failure: An oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int 52 (Suppl 62):S23-S28, 1997
24. AOYAMA I, SHIMOKATA K, NIWA T: Combination therapy with benazepril and oral adsorbent ameliorates progressive renal fibrosis in uremic rats. Nephron 90:297-312, 2002
25. NIWA T, MIYAZAKI T, HASHIMOTO N, et al: Suppressed serum and urine levels of indoxyl sulfate by oral sorbent in experimental uremic rats. Am J Nephrol 12:201-206, 1992
26. AOYAMA I, MIYAZAKI T, NIWA T: Preventive effects of an oral sorbent on nephropathy in rats. Miner Electrolyte Metab 25:365-372, 1999
27. AOYAMA I, SHIMOKATA K, NIWA T: Oral adsorbent AST-120 ameliorates interstitial fibrosis and transforming growth factor-beta1 expression in spontaneously diabetic (OLETF) rats. Am J Nephrol 20:232-241, 2000
28. MOTOJIMA M, NISHIJIMA F, IKOMA M, et al: Role for 'uremic toxin' in the progressive loss of intact nephrons in chronic renal failure. Kidney Int 40:461-469, 1991
29. NIWA T: Organic acids and the uremic syndrome: Protein metabolite hypothesis in the progression of chronic renal failure. Semin Nephrol 16:167-182, 1996
30. NIWA T, ISE M, MIYAZAKI T, MEADA K: Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uremic rats. Nephron 65:82-87, 1993
31. TAKAHASHI S, KAWARABAYASI Y, NAKAI T, et al: Rabbit very low density lipoprotein receptor: A low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci USA 89:9252-9256, 1992
32. JOKINEN EV, LANDSCHULTZ KT, WYNE KL, et al: Regulation of the very low density lipoprotein receptor by thyroid hormone in rat skeletal muscle. J Biol Chem 269:26411-26418, 1994
33. WEBB JC, PATEL DD, JONES MD, et al: Characterization and tissue-specific expression of the human 'very low density lipoprotein (VLDL) receptor' mRNA. Hum Mol Gen 3:531-537, 1994
34. LIANG K, VAZIRI ND: Downregulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int 51:1933-1937, 1997
35. KLIN M, SMOGORZEWSKI M, NI Z, et al: Abnormalities in hepatic lipase in chronic renal failure: Role of excess parathyroid hormone. J Clin Invest 97:2167-2173, 1996
36. YAMAKADO M, ISE M: Mechanism of oral adsorbent AST-120 in lipid abnormalities in experimental uremic rats. Kidney Int 56 (Suppl 71):S190-S192, 1999
37. OSCHRY Y, EISENBERG S: Rat plasma lipoproteins: re-evaluation of a lipoprotein system in an animal devoid of cholesteryl ester transfer activity. J Lipid Res 23:1099-1106, 1982
38. VAZIRI ND. Molecular mechanism of lipid disorders in nephrotic syndrome (Nephrology Forum). Kidney Int 63:1964-1976, 2003
39. VAZIRI ND, LIANG K, PARKS JS: Downregulation of hepatic lecithin-cholesterol ester acyltransferase (LCAT) gene expression in chronic renal failure. Kidney Int 59:2192-2196, 2001